TScan Therapeutics, Inc. (TCRX) on Monday announced the appointment of Jason A. Amello as its Chief Financial Officer.
Gavin MacBeath, Ph.D., Chief Executive Officer, expressed confidence in Amello's corporate experience, emphasizing the strategic timing of his appointment as the company advances its clinical-stage programs.
With nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry, Amello joins TScan from Candel Therapeutics, Inc., where he served as the Chief Financial Officer, Treasurer, and Secretary.
Prior to this, he held various finance leadership positions at Saniona AB, Akebia Therapeutics, Inc., and Ziopharm Oncology, Inc. (now Alaunos Therapeutics, Inc.), overseeing multiple equity and debt financings, an IPO, and contributing to a merger of equals. Before that, Amello held multiple finance leadership positions at Genzyme Corporation (acquired by Sanofi AG), including Senior Vice President and Chief Accounting Officer from 2000 to 2011.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.